Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study
Biomolecules and Biomedicine · 2024
DOI: 10.17305/bb.2024.10512 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Biomolecules and Biomedicine, 2024. Verfasst von Nargiz Majidova und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Protein Kinase Inhibitors, Sunitinib. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Many developing countries lack access to recommended first-line treatments for metastatic renal cell carcinoma (mRCC), such as immune checkpoint inhibitors (ICIs) or ICI-tyrosine kinase inhibitor (TKI) combinations. As a result, predictive markers are necessary to identify patients who may benefit from single-agent TKIs for long-term response. This study aims to identify such parameters. This was a multi-centre, retrospective study of patients with mRCC who were undergoing first-line treatment with sunitinib or pazopanib. Patients who had been diagnosed with mRCC and had not experienced disease progression for 36 months or more were deemed to have achieved a long-term response. Predictive clinical and pathological characteristics of patients who did not experience long-term disease progression were investigated. A total of 320 patients from four hospitals were included in the study. The median age of the patients was 60 years (range 20-89 years). According to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classification, 109 patients were classified as having favourable risk and 211 were in the intermediate-poor risk group. The median progression-free survival (PFS) and overall survival (OS) for all patients were 12.5 months and 76.4 months, respectively. In the long-term responder’s group, the median PFS was 78.4 months. Among all patients, prior nephrectomy, the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
- Department of Internal Medicine, Division of Medical Oncology, Kocaeli University, Kocaeli, Turkey.
- Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey.
- Department of Internal Medicine, Division of Medical Oncology, Professor Dr Cemil Tascioglu City Hospital, Istanbul, Turkey.
Zitieren
APA
Majidova, N., Seyyar, M., Bayraktar, D. I., Dinç, G., İsgandarov, E., Huseynov, J., Yaşar, A., Çelebi, A., Sever, N., Kocaaslan, E., Erel, P., Ağyol, Y., Güren, A. K., Arıkan, R., Işık, S., Ercelep, Ö., Demirağ, G., Kefeli, U., Köstek, O., …, & Sarı, M. (2024). Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2024.10512
Vancouver
Majidova N, Seyyar M, Bayraktar DI, Dinç G, İsgandarov E, Huseynov J, et al. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study. Biomolecules and Biomedicine. 2024. doi:10.17305/bb.2024.10512
BibTeX
@article{Majidova2024,
author = {Majidova, Nargiz and Seyyar, Mustafa and Bayraktar, Demet Işık and Dinç, Gülhan and İsgandarov, Elfag and Huseynov, Javid and Yaşar, Alper and Çelebi, Abdussamet and Sever, Nadiye and Kocaaslan, Erkam and Erel, Pınar and Ağyol, Yeşim and Güren, Ali Kaan and Arıkan, Rukiye and Işık, Selver and Ercelep, Özlem and Demirağ, Güzin and Kefeli, Umut and Köstek, Osman and Bayoğlu, İbrahim Vedat and Sarı, Murat},
title = {Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study},
journal = {Biomolecules and Biomedicine},
year = {2024},
doi = {10.17305/bb.2024.10512}
}
EUVIMED